No Picture

Halozyme Announces First Clinical Dosing In argenx’s Phase 1 Trial Of Efgartigimod (ARGX-113) With ENHANZE® Drug Delivery Technology

SAN DIEGO, July 17, 2019 /PRNewswire/ —¬†Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced that argenx has dosed the first subject in a phase 1 clinical trial … […]